Quantcast
Last updated on April 25, 2014 at 5:25 EDT

Latest Gene therapy Stories

2011-07-29 06:00:00

CHICAGO, July 29, 2011 /PRNewswire/ -- Errant Gene Therapeutics, LLC ("EGT"), a pioneering boutique drug development firm specializing in Rare Diseases, announced the transfer of its clinical grade lentiviral vector, TNS 9.55.3, to Memorial Sloan Kettering Cancer Center ("MSKCC"). TNS 9.55.3 developed by EGT pursuant to an exclusive license agreement with Sloan Kettering Institute (SKI), will be used for MSKCC's upcoming beta Thalassemia human clinical trial. The trial protocol provides...

2011-07-26 06:16:00

LONDON, July 26, 2011 /PRNewswire/ -- Great Ormond Street Hospital has announced that a team led by scientists at its research partner, UCL Institute of Child Health (ICH), funded by the Medical Research Council (MRC) and AVI BioPharma, have made an important breakthrough in the development of a treatment for Duchenne Muscular Dystrophy (DMD). Together with the MDEX Consortium, chaired by the ICH's Professor Francesco Muntoni, the group showed that a gene based drug...

2011-07-22 06:47:59

(Ivanhoe Newswire)--A promising gene therapy might just be the next great thing in preventing heart failure. Researchers at Thomas Jefferson University's Center for Translational Medicine have been working on finding a way to prevent and reverse congestive heart failure. These cardiology researchers demonstrated the feasibility and long term effectiveness as well as safety of S100A1 gene therapy in a large animal model of heart failure. This therapy works by raising diminished levels of...

2011-07-21 14:08:00

BOSTON, July 21, 2011 /PRNewswire-USNewswire/ -- The U.S. Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome (WAS). After its implementation in Paris and London, this trial based on preclinical research performed at Genethon (Evry, France) which also manufactures the GMP gene therapy product, is now going to be launched in Boston. It's one of the first international clinical...

2011-07-21 14:13:29

Mucosal epithelia are well-protected against pathogenic germs. However, individual viruses, such as the HI virus, still manage to enter the body via the mucous membrane somehow. Cell biologists from the University of Zurich have now identified a new infection mechanism, demonstrating that the viruses use the body's own scavenger cells for the infection. The new findings are important for cancer-gene therapy and the development of anti-viral medication. Mucosal epithelia do not have any...

2011-07-20 17:26:03

Cardiology researchers at Thomas Jefferson University show therapeutic effectiveness and safety of 'next great thing in heart failure' for humans A promising gene therapy developed, in part, at Thomas Jefferson University's Center for Translational Medicine to prevent and reverse congestive heart failure is on the verge of clinical trials, after years of proving itself highly effective in the lab and a large animal study. Reporting in the online July 20 issue of Science Translational...

2011-07-11 05:01:00

SAN DIEGO, July 11, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, announced today that the company will present at the Annual DNA Vaccines Conference, hosted by the International Society of DNA Vaccines, July 12-14 at the Loews Coronado Bay hotel in San Diego, California. This year's conference is themed, "Building on Clinical Progress and Exploring New Targets." (Logo:...

2011-07-08 00:00:00

AMSTERDAM, July 7, 2011 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has filed a request for re-examination of the Marketing Authorisation Application for Glybera(R)with the European Medicines Agency. Glybera is a gene therapy for the genetic disorder lipoprotein lipase deficiency. The Company expects that the re-examination of the dossier will be completed by the end of 2011. About...

2011-07-06 00:00:00

AMSTERDAM, July 6, 2011 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced the appointment of Dr. Carlos R. Camozzi as Chief Medical Officer. Dr. Camozzi brings to AMT more than 25 years of pharmaceutical industry experience, most recently within the orphan drug field. This includes overseeing product approvals at the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA). "We...

2011-06-29 12:27:17

Researchers at Mount Sinai School of Medicine have found in a Phase II trial that a gene therapy developed at Mount Sinai stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population. The data are published online in the June 27 issue of the American Heart...